Colon and rectum cancer are considered the third leading cause of cancer death in both sexes. Colon and rectum cancer patient survival depends on the stage at which the tumor is detected, but only 12% of the adult population participates in cancer population screening programs because conventional screening includes invasive procedures such as sigmoidoscopy and colonoscopy.
The test consists of detecting the methylated form of the Septin 9 gene (mSEPT9) in plasma. Methylation of the Septin 9 gene (mSEPT9) is a process that occurs early in tumor development. The mSEPT9 passes through the blood as free DNA and can be detected in plasma in more than 90% of colon tumors; therefore, it is a good tumor marker.
• General population, both men and women, asymptomatic, from the age of 50 years.
• People who do not perform routine colonoscopy, according to the recommendations of the screening programs for colon and rectal cancer.
Real-Time Polymerase Chain Reaction
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Approved by the FDA (Food and Drug Administration).
• High sensitivity and specificity and detects all types of colorectal cancer, regardless of its location.
• Outcomes far superior to current faecal screening techniques. Consequently, this is an analysis that can easily be repeated yearly or biannually.
• Improves patient acceptance to do the test and to adhere to programs for colon and rectum cancer screening (sigmoidoscopy and colonoscopy).
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent.
• Clinical Questionnaire.
• It is not recommended performing this test in pregnant women, since mSEPT9 is involved in normal embryonic development.
• It is not a substitute for colonoscopy.
• Fasting is not necessary for the test.